The latest issue of the Rx Compliance Report included summaries of our posts, a flock of pharmas and why benchmarking matters.
We’re happy to be included. Most of the forty drug companies subscribe to the newsletter, as do the law firms that help them. For ten years, Rx Compliance has been chronicling the ‘government’s crackdown on pharmaceutical sales and marketing practices.’ That crackdown is gaining speed.
The Wall Street Journal reported this week that Pfizer will pay about $60 million to settle alleged FCPA violations. In April, Johnson & Johnson resolved FCPA offenses by paying $70 million.
Our 2011 corporate investigations list included Pfizer, as well as AstraZeneca, Biomet, Bio-Rad Laboratories, Bristol-Meyers Squibb, Covidien, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Orthofix International, Sciclone Pharmaceuticals, Smith & Nephew, Stryker Corporation, Talecris Biotherapeutics, and Zimmer.
The same issue of Rx Compliance ran a front-page story about Jeff Kaplan’s view of global enforcement trends. Kaplan, co-author of the anti-corruption compliance program benchmarking survey, also described ‘five practical benchmarks in anti-corruption efforts.’
Comments are closed for this article!